GetTopicDetailResponse(id=366f1852e1, topicName=Achillion, introduction=Achillion, content=null, image=null, comments=3, allHits=717, url=https://h5.medsci.cn/topic?id=1852, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=94844, tagList=[TagDto(tagId=94844, tagName=Achillion)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1778988, encodeId=583d1e7898897, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, objectTitle=Achillion的D因子抑制劑Danicopan治療陣發(fā)性夜間血紅蛋白尿，獲得FDA突破性療法指定, objectType=article, longId=180107, objectId=1e3218010eb7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e3218010eb7, replyNumber=0, likeNumber=94, createdTime=2020-07-06, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e3218010eb7, moduleTitle=Achillion的D因子抑制劑Danicopan治療陣發(fā)性夜間血紅蛋白尿，獲得FDA突破性療法指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1e3218010eb7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1778987, encodeId=65cb1e78987f4, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, objectTitle=禍不單行，艾伯維、Achillion相繼爭奪吉利德丙肝藥市場, objectType=article, longId=44783, objectId=969944e8346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969944e8346, replyNumber=0, likeNumber=90, createdTime=2015-01-30, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969944e8346, moduleTitle=禍不單行，艾伯維、Achillion相繼爭奪吉利德丙肝藥市場, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=969944e8346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1778986, encodeId=295e1e78986f2, content=<a href='/topic/show?id=366f1852e1' target=_blank style='color:#2F92EE;'>#Achillion#</a>, objectTitle=Achillion丙肝藥物ACH-3102二期臨床數(shù)據(jù)良好有望挑戰(zhàn)Sovaldi, objectType=article, longId=39211, objectId=2b2b39211da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b2b39211da, replyNumber=0, likeNumber=72, createdTime=2015-02-27, rootId=0, userName=makuansheng, userId=2ba9118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b2b39211da, moduleTitle=Achillion丙肝藥物ACH-3102二期臨床數(shù)據(jù)良好有望挑戰(zhàn)Sovaldi, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2b2b39211da)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
